Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | TPH1 | P17752 | 1/20 | 0.33 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25121126 | 0.89 | DRD2 (0.42) | PDE10ATP53 | |
| SCHEMBL26541113 | 0.82 | PDE10A (0.35) | PDE10AAGTR1AGTR2PPARGHDAC1 | |
| SCHEMBL26160462 | 0.82 | MEN1 (0.41) | PDE10AMEN1KMT2ATP53TPH1 | |
| SCHEMBL26483189 | 0.79 | GLP1R (0.45) | AGTR1AGTR2PPARGMEN1KMT2A | |
| SCHEMBL3059937 | 0.79 | NTRK1 (0.47) | AGTR1AGTR2PPARGNTRK1NTRK2 | |
| SCHEMBL26541120 | 0.77 | KCNH2 (0.33) | PDE10A | |
| SCHEMBL26541207 | 0.77 | GLP1R (0.42) | AGTR1AGTR2PPARGMEN1KMT2A | |
| SCHEMBL25465763 | 0.76 | GLP1R (0.49) | — | |
| SCHEMBL27111062 | 0.76 | PPARG (0.47) | PPARGTP53HDAC6 | |
| SCHEMBL26541392 | 0.74 | PDE10A (0.36) | PDE10AMEN1KMT2ATP53TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | PDE10A 144/4885AGTR1 143/4885AGTR2 264/4885 |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | PDE10A 144/4885AGTR1 143/4885AGTR2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.